Table 1 Omalizumab treatment effectiveness
From: Long-term benefits of omalizumab in a patient with severe non-allergic asthma
Outcomes | Basal | Basal (post beta agonist) | 32-week | 3-years | 3-years (post beta agonist) |
|---|---|---|---|---|---|
GETE rating | Â | Â | Excellent | Excellent | Â |
AQLQ (median, range) | 1.71 | 3.23 | 5.43 | Â | |
FEV1 % | 46% | 60% | 40% | 53% | 71% |
FEV1/FVC | 0.49 | 0.49 | 0.46 | 0.49 | 0.57 |
FEF25% | 25% | 30% | 12% | 26% | 33% |
FEF50% | 15% | 18% | 13% | 18% | 22% |
FEF75% | 16% | 14% | 13% | 13% | 15% |
Hospitalization | 2 | 0 | 0 | Â | |
Exacerbation mild + moderate | 5 for year | 0 | 2 (-60%) | Â | |
IgE | 272.6 IU/ml | Â | 419 IU/ml | Â | |